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Any day, while we are all distracted by the fire and smoke
arising from the great debates onhealth care reform, thatman-
date could slip under the radar as an amendment or rider to a
totally unrelated congressional bill, like the creation of the
FCCCER included in the $787 billion Recovery Act of 2009.8
The elderly, who are affected most by this disease, may then
awake to find that they aremandated to enter a painful new era
on a road paved by research studies such as these.
Such an outcomemust be clear toDrWeinstein who, in his
editorial in the same issue of theNew England Journal of Med-
icine,9 clearly recognized that these studies will be used by the
government for exactly this purpose. I wish to remindhim that
it is one thing to tell a patient whom you do not know that he
or she cannot have vertebroplasty on the basis of studies, re-
gardless of whether they are as flawed as these studies, and it is
quite another thing entirely to be either the patient whose life
is limited by pain or a caregiver. I wonder whether the authors
of these research studies and Dr Weinstein would proudly
refuse vertebroplasty for themselves or their mothers in such a
situation. If so, then let them find comfort in their own med-
icine. I am certain that their mothers would have a different
opinion.
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COMMENTARY
Response to “Randomized
Vertebroplasty Trials: Bad News or
Sham News?”
We appreciate the opportunity to respond to the thought-ful editorial regarding our studies investigating the effi-
cacy and safety of vertebroplasty that were published recently
in the New England Journal of Medicine.1,2 The author of the
editorial presents his personal anecdotal experience of suc-
cessful outcomes of vertebroplasty as “evidence” that verte-
broplasty is efficacious, while suggesting that our results,
based on the most rigorous of study designs, the randomized
placebo-controlled trial, are erroneous. We would point out
that the findings in our 2 independent studies of statistically
significant and clinically important improvement, both im-
mediate and sustained, following the procedure are in keeping
with his anecdotal experience and the results of previous stud-
ies. The magnitude of improvement in pain in the vertebro-
plasty-treated groups was similar in the 2 trials and consistent
with improvements reported in previous uncontrolled and
controlled augmentation trials, including the VERTOS and
Fracture Reduction Efficacy (FREE) studies.3,4
In contrast to previous studies, our trials compared the
experiences of those who received vertebroplasty with those
who received a sham procedure with the added methodologic
constraint that treatment allocation was blinded in both par-
ticipants and the outcome assessors, thereby reducing the po-
tential for bias in estimating the treatment effect. Both trials
observed that subjects in the control groups improved follow-
ing the procedure, with neither trial demonstrating a differ-
ence between the active and placebo groups in the magnitude
of improvement in pain or functional status. It would appear
that it is this observation that is most difficult for the author of
the editorial and others to accept. As discussed in both of our
articles, possible explanations for a discordance between the
perceived results of clinical practice and the results of un-
blinded uncontrolled studies versus the findings from blinded
placebo-controlled trials include the self-limited natural his-
tory of vertebral fractures, regression to the mean, and the
placebo response. While we consider it unlikely that local an-
esthesia would have a sustained effect, investigators at 1 site
have already undertaken new trials to further probe the rele-
vance of local anesthesia in painful vertebral fractures.
The author casts doubt on the validity of our trials by
questioning the vertebroplasty techniques used in our stud-
ies. We are not aware of any evidence to support his view
that the cement volume in our trials was suboptimal. The
investigators of 1 of the trials previously found no associa-
tion between cement volume and patient outcomes follow-
ing vertebroplasty.5
Although neither trial reached the prespecified sample
sizes, both trials hadmore than adequate power to detect clin-
ically important differences between groups with respect to
their primary efficacy end points. The a priori target sample
size for the Australian trial1 was large because the trial was also
designed to test other hypotheses regarding safety, including
incident fracture rate, which would have required a larger
sample size. The Investigational Vertebroplasty Efficacy and
Safety Trial (INVEST) was initially powered to detect very
small differences in outcome, far less than the minimally clin-
ically relevant difference in pain and function. The investiga-
tors of both trials would have been thrilled to enroll more
patients, but recruitment was hampered by the widespread
acceptance and availability of the treatment in both trial set-
tings. Recent estimates indicate that well over 150,000 aug-
mentation procedures are done annually in the United States.
Vertebroplasty has been publicly funded in Australia since
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November 2005, after which referral to the Australian study
enrollment declined.
The author raises legitimate issues regarding the crossover
rates and treatment results in eligible but nonenrolled patients
in the INVEST trial. We are actively investigating these issues.
We would point out, though, that crossover was nearly non-
existent before our primary outcome assessment at 1 month;
thus, the differential rates of crossover do not invalidate our
primary efficacy results. The author of the editorial notes con-
cern about potential unblinding with time, but we should em-
phasize that unblinding would serve to increase, rather than
decrease, the apparent benefit of augmentation (patients who
knew they received vertebroplasty would be expected to have
greater pain relief than patients who knew they received the
control procedure). Even if unblinding did occur, the obser-
vation that the mean pain improvement was nearly identical
between groups casts further doubt on the efficacy of cement
in relieving pain.
We have had experiences similar to those of the author of
“miracle cures” following vertebroplasty in our usual clinical
practices.However, unbiased blinded assessment in both trials
yielded similar observations of “miracle cures” in both the
vertebroplasty and the control intervention groups. It is also
important to note that vertebroplasty is not without risk—1
patient in the vertebroplasty group in the INVEST trial had a
thecal sac tear and 1 patient in the vertebroplasty group in the
Australian trial developed osteomyelitis. Whether vertebro-
plasty increases the risk of further vertebral fractures is still
open to debate.
Publication of the INVEST and Australian vertebroplasty
studies represents a fork in the road for augmentation and
interventional radiology in general. We could ignore the trials
or try to show that they were fatally flawed and continue to
practice augmentation as always, or we could accept the trial
results and cease augmentation altogether. A third approach
would be to carefully consider the strengths and weaknesses of
all available augmentation research to date to determine
whether further studies are warranted. If the author of the
editorial or others or both still believe that augmentation con-
fers large benefits that outweigh any potential risks, then the
onus is on them to prove it in high-quality, well-designed
studies.
Judging from the early vociferous response to these trials, it
would appear to us that many practitioners will only embrace
evidence that supports their pre-existing beliefs. Because of
these trials, perhaps more practitioners can be convinced to
turn away from “belief-based medicine” and toward “evi-
dence-based medicine.”
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